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ABSTRACT
Accessing the nucleus through the surrounding
membrane poses one of the major obstacles for
therapeutic molecules large enough to be excluded
due to nuclear pore size limits. In some therapeutic
applications the large size of some nucleic acids,
like plasmid DNA, hampers their access to the
nuclear compartment. However, also for small oli-
gonucleotides, achieving higher nuclear concentra-
tions could be of great benefit. We report on the
synthesis and possible applications of a natural
RNA 5’-end nuclear localization signal composed
of a 2,2,7-trimethylguanosine cap (m3G-CAP). The
cap is found in the small nuclear RNAs that are con-
stitutive part of the small nuclear ribonucleoprotein
complexes involved in nuclear splicing. We demon-
strate the use of the m3G signal as an adaptor
that can be attached to different oligonucleotides,
thereby conferring nuclear targeting capabilities
with capacity to transport large-size cargo
molecules. The synthetic capping of oligos
interfering with splicing may have immediate clinical
applications.
INTRODUCTION
Nucleocytoplasmic transport of endogenous molecules is
a regulated process where small molecules can diﬀuse
through the nuclear pore complex of the nuclear mem-
brane, while molecules >40KDa require the use of a
signal and energy-mediated processes. Import of nuclear
proteins requires nuclear localization signals (NLS) in the
form of speciﬁc amino-acid sequences which mediate the
interaction with carrier proteins (1). The best studied NLS
sequence is the SV40 large-T antigen. It mediates the inter-
action between the cargo protein, bearing the NLS signal,
and an import receptor consisting of an adaptor protein,
importin a, which directly binds the NLS signal, and
importin b which is the mediator of the actual import
process through the nuclear pores (2).
An archetypical NLS, which is mediating the interac-
tion with several diﬀerent types of import receptors, is
found on the ribosomal L23a protein. This NLS, which
has a higher degree of complexity and harbours very basic
regions, is thought to have evolved prior to the evolution-
ary divergence of import receptors (3).
In addition to the cargo and import receptor interac-
tions, there are other factors needed in the process of
nuclear import. It is the asymmetric distribution of the
factors Ran, RCC1, RanGAP1 and RanBP1, creating a
steep RanGTP gradient across the nuclear envelope that
allows the directional movement of the cargo–importin
receptor complex to the nucleus (4,5).
Apart from nuclear proteins some RNAs, in the form of
small nuclear ribonucleoprotein complexes (snRNP), use
signals for nuclear import. These RNAs are comprised of
the major spliceosomal U snRNAs, such as U1, U2, U4
and U5 and are the major building units of the spliceoso-
mal complex. U snRNAs are transcribed in the nucleus
by RNA polymerase II after which they acquire a
7-methylguanosine (m
7G) cap structure at their 50-end.
This cap structure acts as a nuclear export signal that is
recognized by the cap-binding complex (CBC). The CBC
complex is in turn recognized by the export receptor
CRM1 with the help of the PHAX adapter leading ulti-
mately to the nuclear export of the U snRNA (6).
After release in the cytoplasm the U snRNA is recog-
nized by the survival of motor neuron complex (SMN)
that directs the proper assembly with a group of Sm
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7G cap is hyper-
methylated to a 50 2,2,7-trimethylguanosine (m3G) cap
structure (Figure 1) by the small-nuclear RNA cap hyper-
methylase (11,12). The matured snRNP is then imported
back into the nucleus. This nuclear transport involves two
diﬀerent pathways and two very distinct import signals,
both of which, however, recruiting importin b (13–16).
The ﬁrst pathway uses a still ill-deﬁned import signal pres-
ent in the Sm core domain of the snRNP formed by the
Sm proteins (17). The second pathway involves the use
of the m3G-CAP structure (18). The m3G-CAP signal is
recognized by the import adaptor protein snurportin
(SPN1) (14,19,20), which in turn is recognized by importin
b (14–16,21).
Nuclear import of therapeutic molecules is of great
importance for many applications. For example, speciﬁc
targeting of exogenous proteins, such as antibodies, to the
nucleus for the purpose of radioimmunotherapy, is seen as
a way to increase cytotoxicity eﬀects in cancer cells (22).
In particular, one of the areas where nuclear targeting has
been getting a lot of attention is the gene delivery/gene
therapy ﬁeld. This is especially true in non-viral or syn-
thetic vector development, since these transport systems
need to mimic most of the virus strategies used to over-
come several cellular barriers of which the nuclear mem-
brane is the ultimate one.
Some approaches to nuclear delivery of nucleic acids,
like plasmid DNA, have relied on the DNA sequence itself
(23). A plethora of other types of strategies for nucleic
acid delivery have been based, however, on the direct or
indirect attachment of NLS peptides to the nucleic acid
molecules as a way to promote binding of the importin
a/importin b heterodimer to the nucleic acid construct and
its subsequent nuclear translocation (24). The SV40 large
T antigen NLS (especially in its shortest form pkkkrkv)
has been one of the most employed NLS peptides. It has
been associated to DNA via ionic interactions (25); via
chemical coupling (26); through the use of peptide nucleic
acids (PNA) linked to the NLS and bound to DNA
in a sequence-speciﬁc manner (27,28); through the use of
a triple helix forming oligonucleotide system (29) and by
the use of biotinylated DNA bound to NLS conjugated
streptavidin (30). An example of another peptide NLS
used is the non-classical NLS deﬁned by the M9 sequence,
coming from the heterogeneous nuclear ribonucleoprotein
(hnRNP) A1, which has been used together with a DNA
binding peptide for increased nuclear delivery after lipo-
fection of non-dividing cells (31).
We are now exploring the possibility to use a diﬀerent
type of signal, the m3G-CAP, for the purpose of enhan-
cing nuclear delivery of nucleic acids. We coupled the m3G
pyrophosphate to 50-phosphorylated 20-O-methyloligori-
bonucleotides to achieve m3G-capped oligonucleotides
resembling the 50-end of endogenous U snRNAs. The
presence of the m3G-CAP clearly showed an increase of
the nuclear delivery of the oligonucleotide together with a
large cargo protein (Streptavidin) after microinjections of
Xenopus oocytes and when using a protein transfection
method for cultured cells that delivers proteins to the cyto-
sol. Furthermore we observe increased splice correction
when the m3G-CAP is connected to an antisense oligonu-
cleotide, which provides a functionally relevant example.
MATERIALS AND METHODS
Synthesis ofm3G-cappedoligonucleotides
p-AS705 and p-PMO2 were converted to the m3G-
capped derivatives by reaction with the m3G-
50-pyrophosphorylimidazolide 5 in a Mn(II) promoted
(32) capping procedure. Synthesis of 5 (Scheme 1), was
modiﬁed compared to previously published procedures
(32,33) which includes a new one-pot, ﬁve-step
50-Pyrophosphate 3 synthesis, based on known reactions
(34–37). First 1 was converted to compound 2. To the pur-
iﬁed compound 2 (171mg, 0.33mmol) in 2ml of dry DMF
was then added salicyl chlorophosphite (1.9 eq, 0.126g,
0.627mmol), whereupon the reaction mixture was stirred
Figure 1. Structure of the 2,2,7-trimethylguanosine cap.
1926 Nucleic Acids Research, 2009, Vol. 37,No. 6at r.t. [under Ar (g)]. After 15min, a solution of tetra(tri-n-
butylamine)pyrophosphate in DMF (2 eq, 0.66mmol,
1.32ml from a 0.5 mM stock solution, which was directly
before reaction vortexed with 0.5ml tri-n-butylamine)
was added. After 20min, a solution of iodine (0.091g, 1.1
eq, 0.363mmol) in 1.5ml pyridine, containing water
(0.33mmol, 0.00 6ml, 1 eq) was added. After an additional
15min ethylenediamine (0.11ml, 1.65mmol, 5 eq) was
added and the reaction was stirred for 1h. Solvents were
evaporated and the crude product was dissolved in
NH3(aq) and left to react overnight. After concentration,
the crude product was dissolved in water and puriﬁed
by preparative RP HPLC using a gradient of buﬀer B
in buﬀer A (0–20% B over 30min). Concentration of
collected fractions gave N
2, N
2-dimethylguanosine
50-pyrophosphate (3) as the tris(triethylamine)salt.
RT=23min. Yield 55.8mg, 22% (over ﬁve steps). 3
Was treated with sat. NH3 in methanol for two days at
r.t. After concentration, the product was dissolved in
water and washed with dichloromethane (3 ), concen-
trated in vacuo, freeze-dried and redissolved in dry
DMF (1ml). Methyl iodide was then added (0.08ml,
1.28mmol, 20 eq) and the reaction was stirred at 408C
for 5h. The solvent was evaporated and the product was
dissolved in water and puriﬁed by preparative RP-HPLC
using a gradient of buﬀer B in buﬀer A (0–10% B over
40min). Evaporation of collected fractions gave N
7, N
2,
N
2-trimethylguanosine 50-pyrophosphate 4 as the tris
(triethylammine)salt (alternatively 4 was synthesized in
an alternative fashion from 3, see Supplementary
Material). Yield 52mg, 20% (after 6 steps, from com-
pound 2). 4 Was then converted to the imidazolide 5,
which was used in reaction with the 50-phosphorylated
oligonucleotides to produce m3G-CAP-AS705 and m3G-
CAP-PMO2 (Table 1).
Oocytemicroinjections, western blot analysis and
fluorescence microscopy
Streptavidin-Alexa488 (Molecular Probes) + oligonucleo-
tide constructs (Figure 2) were formed by incubating 3mg
STV (Streptavidin) reconstituted in 1  phosphate buﬀer
saline (PBS, pH 7.4) with 2–4 times molar amount of
biotinylated oligo constructs. The volume was adjusted
with nuclease free water (Qiagen) to have a ﬁnal concen-
tration of 329 ng STV/ml and the incubation proceeded for
2h at r.t. and if not used the same day the constructs were
stored at 48C.
Prior to microinjections, the prepared STV-oligo con-
structs were spun down at 16000g for 5min. A volume of
41.4 nl of STV-oligo constructs were injected in the cyto-
plasm of the oocyte using the Nanoinjector 2000
TM pump
(World Precision Instruments, Inc.) followed by incuba-
tion at 198C in OR2 buﬀer for 4h. After incubation,
oocyte nuclei were manually dissected in nuclear dissec-
tion buﬀer (140mM KCl; 0.5mM MgSO4; 20mM
Tris–HCl pH 7.2) and collected directly in 2  Laemelli
sample buﬀer. Collected nuclei were then analysed by
western blot (for details see Supplementary Material).
Fluorescence microscopy imaging details are provided in
the Supplementary Material.
Streptavidin-oligo complextransfections
U2OS cells were seeded on top of coverslips in a 24-well
plate with DMEM+10% FCS the day before transfection
so that they were conﬂuent or close to conﬂuency the next
day. Streptavidin-Alexa488 (Molecular Probes) + oligo-
nucleotide constructs (Figure 2) were formed by incubat-
ing 2mg STV (Streptavidin) reconstituted in 1 PBS (pH
7.4) buﬀer with 2–4 times molar amount of biotinylated
oligo constructs for 2h at r.t. 20 mM HEPES buﬀer
Scheme 1. Synthesis of the m3G5 0-pyrophosphateimidazolide. Reagents and conditions: (i) a: Py/NH3aq sat., 3h, r.t.,; b: MMTrCl, Py/DMF,
24h, r.t.; c: BzCl, Py, r.t., 24h, D 80% AcOH, r.t., 5h; (ii) a: salicyl chlorophosphite, r.t., 15min; b: tri-n-buthylammine pyrophosphate, DMF, r.t,
20min; c: I2, Py/H2O, r.t, 15min; d: ethylenediamine, r.t., E NH3aq sat., 08C 48h; (iii) MeI, DMF, 408C, 5h; (iv) imidazole, triphenylphosphine,
di-2-pyridyldisulphide, DMF 24h. Py, pyridine; MMTrCl, monometoxy trityl chloride; DMF, dimethylformamide; r.t.=room temperature; BzCl,
benzoyl chloride; AcOH, acetic acid; MeI, methyl iodide.
Nucleic Acids Research,2009, Vol.37, No. 6 1927(pH 7.4) was then used to bring the total volume up to
100ml and then 3.5ml of PULSin transfection reagent
(PolyPlus-Transfection, NY, USA) was added. The mix-
ture was vortexed and left to incubate for 15min at r.t.
During this incubation time, the cells were washed twice
with PBS and 900ml of pre-warmed OPTI-mem I
(Invitrogen) was added to the wells. The PULSin com-
plexes were then added to the cells and left to incubate
for 4h. Subsequently, the medium was discarded and the
cells washed twice with pre-warmed OPTI-MEM I.
Finally, 400ml of OPTI-MEM I was added to the wells
after which the cells were further incubated for 2–3h.
Cells were then analysed by ﬂuorescence microscopy and
confocal microscopy (for details see Supplementary
Material).
Oligonucletide transfections
HeLa/Luc705 cells were pre-seeded at a density of 35000
cells per well in a 24-well plate the day before transfection,
in order to have between 40% and 50% conﬂuency the
next day. Antisense oligonucleotide constructs were trans-
fected by using Oligofectamine reagent (Invitrogen)
and following the manufacturer’s protocol. Cells were
harvested in Luciferase lysis buﬀer (25mM TAE, 10%
glycerol, 1mM EDTA, 1% Triton-X100) after 24h and
the level of luciferase expression was analysed based on a
luciferase activity assay (Luciferase Assay Kit, Biothema
AB, Handen, Sweden). Total protein was measured using
a BCA protein assay (Micro BCA
TM protein assay kit,
Thermo Scientiﬁc-Pierce Protein Research Products,
Rockford, USA). RT–PCR was done by isolating total
RNA from cells with RNeasy plus kit (QIAGEN) from
which a total of 3ng of RNA was then used in each
reaction (total volume per reaction was 20 ml) with the
ONE STEP RT-PCR kit (QIAGEN) and following the
manufacturers protocol. The primers used were: Fwd-TT
GATATGTGGATTTCGAGTCGTC; Rev-TGTCAATC
AGAGTGCTTTTGGCG. The program for the RT–
PCR was as follows: (558C, 35min+958C, 15min) 1
cycle+(948C, 30s+558C, 30s+728C, 30s) 29–30
cycles+728C, 10min ﬁnal extension. The PCR products
were analysed in a 2% agarose gel in 1  TBE buﬀer and
visualized by SYBR-Gold (Invitrogen, Molecular Probes)
staining. Gel images were captured by a Fluor-S gel
documentation system (BioRad) with the Quantity One
software (BioRad).
Table 1. Oligonucleotides
Name Sequence
p-AS705 (oligo p1) pAUACCUCUUACCUCAGUUACA
p=phosphate group
AUA=U snRNA common 50-end cap sequence
N=20-O-methyl RNA bases
m3G-CAP-AS705
(oligo Cp1)
m3GpppAUACCUCUUACCUCAGUUACA
p= phosphate group
AUA = U snRNA common 50-end cap sequence
m3G=2,2,7-trimethyl Guanosine CAP
N=20-O-methyl RNA bases
p-AS705scr (oligo p2) pAUAACUACCCGAUAUCUCCUC
m3G-CAP-AS705scr
(oligo Cp2)
m3GpppAUAACUACCCGAUAUCUCCUC
p-PM02 (oligo2) pAUAAGAGA-L-b
p=phosphate group
L=34 atom linker
b=biotin
N=20-O-methyl RNA bases
m3G-CAP-PM02
(oligo2CAP)
m3GpppAUAAGAGA-L-b
L=34 atom linker (see below)
b=biotin (see below)
m3G=2,2,7-trimethyl Guanosine CAP
N=20-O-methyl RNA bases
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In Figure 3, a paired t-test with two-tailed P-value
was used for analysis; In Figure 5, the 2 2 contin-
gency table was analysed by the Fisher’s exact test with
two-tailed P-value.
RESULTS
m3G cappedRNA oligonucleotides are ableto directnuclear
accumulation of acargoprotein inXenopus oocytes
The use of Xenopus oocytes for the analysis of nuclear
transport is a very well characterized system oﬀering
many advantages for this type of studies (38–41). First,
they are very big cells with a large nucleus and easy to
inject; second, it is quite straightforward to study the iso-
lated compartments (cytoplasm and nuclei), since the
nuclei are relatively easy to isolate by manual dissection.
A further very important feature is that the oocyte is a
non-dividing cell, which thereby maintains its nuclear
membrane integrity throughout the experiments. Yet
another reason to use the Xenopus oocyte for the initial
analysis of m3G-capped oligos was that many studies deal-
ing with import mechanisms of U snRNAs were initially
done using these cells (12,18,38,42).
We decided to study the nuclear accumulation of a con-
struct constituted of a ﬂuorescent Streptavidin (STV)
bound to 2–4 biotinylated 20-O-methyl RNA oligos with
(CAP-PM02) or without (p-PM02) m3G-CAP modiﬁca-
tion (Figure 2). The STV protein itself has a molecular
weight of around 53 KDa and the addition of 2–4 bioti-
nylated oligos equals a total MW for the construct of
approximately 60–70 KDa. This should make it diﬃcult
for the STV-oligo construct to enter the nucleus by passive
diﬀusion alone, since 45–50 KDa is the known cut-oﬀ of
the nuclear pore. The cargo STV was linked through a
long spacer to the carrier oligo, providing insight into
the possibility of using the m3G-CAP signal distanced
from its cargo.
Injections into the oocyte cytoplasm of STV-oligo con-
structs with or without added m3G-CAP were performed
and after an incubation period of 4h the nuclei were man-
ually dissected to check for the relative amounts of STV
protein that had been directed to the nuclear compart-
ment. By analysing the amounts of STV recovered from
the nuclear compartment with the use of western blot
(Figure 3A), we veriﬁed that the addition of m3G-CAP
oligos enhanced nuclear uptake at least 6-fold compared
to the non-capped oligos.
There was still some STV recovered from the nucleus of
oocytes injected with the non-capped oligo versions. This
may be due to the fact that the outer nuclear membrane is
in direct contact with the cytoplasm, hence there might be
some residual unspeciﬁc binding of STV to the nuclear
membrane. Due to this, the 6-fold higher nuclear uptake
seen with the m3G-CAP may thus be regarded as the min-
imal diﬀerence. We can, however, not exclude that some
STV-oligo complexes diﬀuse passively into the nucleus,
since the total MW of the constructs is close to the nuclear
pore cut-oﬀ size.
In addition to western blot analysis, we performed ﬂu-
orescent microscopy of isolated nuclei after cytoplasmic
injections of the STV complexes. As can be seen in
Figure 4, the nuclei were isolated in pairs each represent-
ing a cytoplasmic injection of STV with (nucleus 1) or
without (nucleus 2) capped oligonucleotide. By putting
the nuclei side by side, it was easily seen that only the
oocyte injected with STV-CAPoligo showed a ﬂuorescent
nucleus. The nucleus from oocytes injected with control
oligo with no m3G-CAP lacked detectable ﬂuorescence
conﬁrming the previous results of the western blot,
where the capped oligo conferred enhanced nuclear trans-
port capacity to the STV-oligo complex.
m3G-cappedRNA oligonucleotides are ableto directnuclear
accumulation of acargoproteinin mammalian cells after
cytosolic delivery by atransfection reagent
We went on to test if the previous constructs would
behave similarly when delivered to a mammalian cell
line and, importantly, by a transfection method that
resembles the delivery routes of many gene transfer pro-
tocols. For this, we employed a method of protein and
peptide delivery through the use of a reagent that pro-
motes uptake of proteins into the cytosol of cells
(PULSin) after endocytosis of protein–reagent complexes.
We ﬁrst tested the feasibility of the method by using
STV constructs bound to 2–3 biotinylated SV40-NLS pep-
tides (pkkkrkv) or biotinylated SV40-mutatedNLS pep-
tides (pktkrkv). When transfected to the cytosol of
U2OS cells these constructs localized preferably either in
the nucleus (SV40-NLS construct >90%) or in the cyto-
plasm (SV40-mutNLS >90%) as observed by the detec-
tion of ﬂuorescence coming from the cargo STV-Alexa488
(data not shown).
We then tested the same constructs used in the Xenopus
oocyte microinjections in the mammalian U2OS cell line.
After transfection of the constructs we saw a completely
diﬀerent pattern between STV-oligo2CAP and STV-
oligo2, both using 2–3 (see Supplementary Figure 5) or
3–4 oligos bound to STV (Figure 5). The cells did not
Figure 2. Schematic representation of the m3G-CAP oligo construct
bound to the Streptavidin-Alexa488 (STV) used in the nuclear trans-
port assays by cytoplasmic microinjections in Xenopus oocytes and by
PULSin protein delivery to the cytosol of a mammalian cell line. Image
proportions are exaggerated for a better understanding.
Nucleic Acids Research,2009, Vol.37, No. 6 1929only show a higher nuclear ﬂuorescence but also a very
speciﬁc pattern, with very prominent nuclear bodies con-
taining most of the STV ﬂuorescence, when the cargo was
attached to the m3G-CAP oligos (Figure 5C). The size of
these ‘STV-m3G-oligo bodies’ was easily correlated to the
amount of STV found in the nuclear compartment and
corresponded to most of the nuclear ﬂuorescence in
contrast to an overall diﬀuse pattern seen when using
STV-NLS peptides.
By using ﬂuorescence microscopy, cells were also enum-
erated using speciﬁc criteria. Cells counted as positive for
enhanced nuclear transport were characterized as having
a more overall nuclear ﬂuorescence with distinct bodies.
Cells assigned as negative were characterized as having
diﬀuse, preferential staining in the cytoplasm or both in
the cytoplasm and nucleus (which argues for that the STV
was not being actively targeted to the nuclei, but instead
could diﬀuse in and out of the nuclear compartment)
(Figure 5D). Following these criteria, we found a very
signiﬁcant diﬀerence (P<0.0001) between the STV con-
structs bound by 3–4 m3G-CAP-oligos (80% predomi-
nantly nuclear) and STV bound by 3–4 nonCAP-oligos
(92% predominant cytoplasmic or overall diﬀuse stain-
ing). For the STV constructs carrying 2–3 oligos, the per-
centages were 92% nuclear and 81% cytoplasmic,
respectively for m3G-CAP and nonCAP attached oligos
(Supplementary Figure 5). It should be noted that when
these STV-oligo constructs were created, together with
the PULSin reagent, some aggregates were still remaining
in the wells (these were visible as random bright spots of
ﬂuorescence of irregular shapes).
Confocal microscopy was used in order to further
conﬁrm the nuclear location of the STV-oligo-CAP
(Figure 6). The line trace proﬁle graphs clearly show the
co-localization of the nuclear stain (DRAQ5 stain repre-
sented by blue colour; blue line) with the ﬂuorescent STV-
oligo-CAP constructs (ALEXA488 green ﬂuorescence;
green line). Inversely, when using the STV-oligo con-
structs with no m3G-CAP the line trace proﬁle clearly
Figure 4. Fluorescence imaging of the accumulation of Streptavidin
complexes in Xenopus oocyte nuclei after cytoplasmic injections.
Oocytes were injected in the cytoplasm with either STV-oligo2 or
STV-oligo2CAP complexes and after 4h incubation the nuclei were
dissected. The nuclei were gently tapped with a glass rod, in order to
release excess cytoplasm that might be still attached to the nuclear
membrane after dissection. Photos were then taken with two nuclei
side by side representing cytoplasmic injections of capped (nucleus 1)
and non-capped (nucleus 2) STV-oligo constructs. (A) Photo taken with
oblique visible light in order to get a phase contrast eﬀect making it
possible to see the almost transparent nuclear membrane; (B) same
nuclei imaged with HBO light and ﬂuorescence FITC ﬁlter; (C) same
nuclei imaged both with low power visible light and with an HBO light
with FITC ﬁlter. A number of 10 pairs of nuclei were analysed with all
of them showing the same pattern as illustrated above.
A
B
Figure 3. Accumulation of Streptavidin complexes in Xenopus oocyte
nuclei after cytoplasmic injections. Oocytes were injected in the cyto-
plasm with either STV-oligo2 or STV-oligo2CAP complexes and after
4h incubation the nuclei were dissected and collected for western blot
analysis. (A) Upper panel shows western blot using anti-Streptavidin
probing. Each lane corresponds to one group of four nuclei pooled
together. Lanes 1–2–7–8: nuclei dissected from oocytes injected with
STV-oligo2CAP (m3G-CAP-PMO2); lanes 3–4–5–6: nuclei dissected
from oocytes injected with STV-oligo2 (p-PMO2). Lower panel shows
a protein loading control by staining the PAGE gel with comassie blue
after transfer. (B) Graph showing the quantiﬁcation of western blot
results by densitometry with normalization to the loading controls
using Fluor-S MultiImager and Quantity One software (BioRad)
(SDs for n=4 are shown).    P<0.005.
1930 Nucleic Acids Research, 2009, Vol. 37,No. 6shows an exclusive cytoplasmic localization. It is possible
to see in the confocal images (Figure 6) as well as in the
regular epiﬂuorescence images (Figure 5) that some ﬂuo-
rescent STV–CAP complexes are outside the nucleus.
We believe these are complexes still entrapped in vesicles
in the cytoplasm or some form of irregular aggregates of
the same complexes. This happened both for the non-CAP
and CAP–STV transfected complexes.
m3G-capped 2’-O-methyl RNA antisense oligonucleotides
show increased efficiency in asplicecorrection assay
Intron splicing is a mechanism occurring only in the nuclei
of cells and for this reason we used a splice correction
assay to check for any increased activity of splice antisense
oligos that could arise from their possible nuclear enrich-
ment by the use of the m3G-CAP signal. We used HeLa/
Luc705 cells stably expressing a luciferase gene, where the
coding region was interrupted by a mutated b-globin
intron at position 705. By targeting the region containing
the mutation with antisense oligos, one can redirect the
splicing so that the luciferase mRNA is successfully trans-
lated into protein (43).
The oligonucleotide used for this study was a
20-O-methyl oligoribonucleotide based on the same
sequence as reported by Kang et al. (43) but with a 3-nt
addition (AUA) to its 50-end. The oligonucleotide
included an overhanging phosphate group at this same
50-end that was used later for the addition of the m3G-
CAP (m3GpppAUA-). After transfection of both oligo
versions, with (oligo1CAP) or without (oligo1) m3G-
CAP addition, we found that the increase of luciferase
activity relatively to untreated HeLa/Luc705 was dose-
dependent and that the capped antisense oligo had an
increasingly higher activity across the concentration
STV-oligo2
Predominant nuclear 
enrichment / distinct 
nuclear body formation
Predominant cytoplasmic or
diffuse fluorescence both in
cytoplasm and nucleus 
With m3G-CAP  164 (80%) 40 (20%) 
Without m3G-CAP  11 (8%) 130 (92%)
*** p value < 0.0001 
A
B
C
D
Figure 5. Localization of ﬂuorescent Streptavidin bound to 3–4 biotinylated 20-O-methyl RNA oligos with (pictures A and B) or without (pictures
C and D)m 3G-CAP (p-PMO2 and m3G-CAP-PMO2 oligos, respectively). Streptavidin-oligo complexes were transfected into U2OS cell lines by the
use of PULSin reagent (protein transfection reagent). After 4h incubation at 378C, cells were washed and incubated for 2h at 378C before ﬂuorescent
microscopy (B and D) and phase contrast pictures (A and C) were taken. Fluorescent microscopy photographs were used to count the cells according
to the described criteria and results are presented in the lower table. N and C mark some nuclei and cytoplasm of cells, respectively, in the phase
contrast pictures. Solid white arrows indicate examples of cells counted as positive for nuclear enrichment; open white arrows point to cells counted
as negative for nuclear enrichment; the open white arrowhead points to aggregates of ﬂuorescent STV complexes occurring during the transfection
procedure; open rectangular boxes were drawn around the ‘STV-m3G-oligo nuclear bodies’ formed by increased accumulation of STV complexes in
the nucleus.
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an  7.9-fold luciferase activity increase for the m3G-
capped oligo version and only 2.3-fold for the uncapped
oligo version (Figure 7A). Thus, we observed a maximum
of 3.4-fold increase in eﬃciency when using the m3G-CAP
signal.
A control oligo with a scrambled sequence was also
tested at the highest concentration with or without m3G-
CAP. Both versions had no eﬀect in correcting aberrant
luciferase splicing attesting to that the m3G-CAP addition
had no eﬀect itself in restoring luciferase activity.
We conﬁrmed the luciferase activity results with
RT–PCR to directly show that the increase in luciferase
activity was due to a correction of the aberrantly spliced
luciferase by the antisense oligos. By subjecting total RNA
from the treated cells to RT–PCR, we show that restora-
tion of luciferase activity is correlated with an increase in
the correctly spliced pre-mRNA and this was always more
eﬃcient when having capped-oligos compared to non-
capped (Figure 7B).
In correlation to the previous results achieved with the
cargo transport, this eﬀect is most likely also due to a
preferential accumulation of the antisense oligo in the
nucleus. Despite the fact that the oligo itself is small
enough to transverse through the nuclear pores by diﬀu-
sion, by having an additional signal for nuclear targeting it
is conceivable that this will shift the equilibrium in the
direction of the nuclear compartment.
DISCUSSION
In this report, we describe a ﬁrst approach to test the
usability of the U snRNA m3G-CAP as an adaptor
signal for the increase of nuclear transport of external
cargoes such as proteins or nucleic acid molecules.
To do this, we initially designed a construct composed
of a ﬂuorescent Streptavidin (STV-Alexa 488) binding a
deﬁned number of RNA oligonucleotides with or without
the m3G-CAP at their 50-ends. We chose initially the
Xenopus oocyte to test our system, since the study of U
snRNAs/snRNP particles has been well documented in
these cells in previous experiments by others. Thus,
using the Xenopus oocyte it was found that nuclear trans-
port of the U1 snRNA species was very much dependent
Figure 6. Confocal imaging of mammalian U2OS cells with STV-oligo complexes transfected by PULSin. Same conditions as for Figure 5 were used
except that for confocal imaging there was further processing such as nuclear staining by DRAQ5 (blue) after cell ﬁxation by 3.7% paraformalde-
heyde in PBS. The line trace proﬁle shows the intensity of the DRAQ5 (blue line in graph) and ﬂuorescent STV-oligo complexes (green line in
graphs) along the drawn line (in red). The confocal pictures conﬁrm the co-localization of the green ﬂuorescence coming from the STV-Alexa488
with m3G-CAP and the localization of the STV-Alexa488 without the CAP only in the cytoplasm of the cell as can be further analysed in the traced
line proﬁle graphs (graph 1 shows the line trace proﬁle over cells transfected with STV-CAP-oligo; graph 2 shows the line trace proﬁles over a cell
transfected with STV-oligo).
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experiments showed that the m3G-CAP was suﬃcient for
enhancing the nuclear import of a cargo protein. More
speciﬁcally, by using a deﬁned construct with 2–4 m3G-
capped RNA oligos, we achieved an at least 6-fold
enhancement in nuclear import as compared to the
uncapped counterpart. To our knowledge, there is
the single study by Rollenhagen and Pante ´ (45), in the
Xenopus oocyte system, where, by pre-forming a complex
composed of non-deﬁned number of m3G-CAPs con-
jugated to gold particles together with recombinant snur-
portin, a signiﬁcant change in nuclear import could be
observed. Here, for the ﬁrst time, we show that the
m3G-CAP is working on its own in the context of a
fully synthetic RNA oligo, which acquires nuclear
import capacities eﬃcient enough to drag an exogenous
cargo protein. Moreover, this was shown to work in a
mammalian cell system.
It is important to point out that, in our study, to
emphasise the possibility that the m3G-CAP can be used
as a speciﬁc adaptor signal, we constructed our cargo–
CAP complexes to have a deﬁned number of m3G-CAP
structures. With this, we showed that a small number
(2–4) of m3G-CAP structures were suﬃcient for providing
nuclear import. Another point worth noting is that the
m3G-CAP is sitting on a short oligo bound to an STV
through the use of a relatively long spacer (34 atoms
long) with biotin at its end (see Supplementary 3.
Structure of the m3G-CAP-PMO2 oligonucleotide and
Figure 2). This shows that the cargo can be spaced away
from the import complex formed by the m3G and the
import receptors, which could be beneﬁcial.
To further test the concept, we used a novel system
where we performed a nuclear import assay in live mam-
malian cells by using a protein delivery reagent that is able
to release the cargo into the cytosol of cells. This system
resembles the pathways taken by molecules in gene deliv-
ery protocols, so we think it should be relevant in asses-
sing the properties of the m3G-CAP for future uses in the
gene delivery ﬁeld. Both complexes with 2–3 or 3–4
(achieving saturation of the streptavidin binding sites)
capped-oligos bound to STV were able to direct nuclear
translocation of cargo eﬃciently. There was some minor
variance in terms of percentage of cells showing nuclear
uptake when using 2–3 or 3–4 oligos bound to STV, 2–3
being slightly more eﬃcient. This slight variance could be
explained simply by small diﬀerences in transfection eﬃ-
ciency due to the reagent itself. Alternatively, it could
be due to the fact that by using 3–4 oligo bound per
STV we are reaching the STV binding site saturation
which then allows free capped-oligos present inside the
cell to compete with the STV bound CAP-oligos for the
import machinery.
As a proof of concept for the application of this nuclear
import strategy in a therapeutic protocol we used a splice
correction assay, where antisense oligonucleotides are
employed to correct a malfunctioning splice occurring
due to a mutation in the b-globin intron. In this
method, the mutated b-globin intron is inserted in the
middle of the luciferase gene whereby targeting the
mutated site with an antisense oligo will restore the luci-
ferase expression by correcting the aberrant splicing (43).
Using antisense oligos with an incorporated m3G-CAP
structure we achieved an enhanced splice correction, mea-
sured by increased activity of a luciferase reporter con-
struct. These results were also conﬁrmed by performing
RT–PCR from the total RNA of the treated cells,
which showed correction of the aberrant splicing at the
mRNA level.
It is worth noting that the splice oligos only carry one
m3G-CAP. In this way, we show that a single cap is suf-
ﬁcient in the context of an oligonucleotide. Natural
snRNAs, always acquire an m3G-CAP after ﬁrst being
recognized and bound by the SMN–assembled protein
complex (7–10), through an enzymatic reaction catalysed
by a hypermethylase (11,12). Importantly, this protein
complex already carries a signal for nuclear import (17).
Thus, our capped-oligonucleotide based system allowed us
to verify that in this context there is no need for the sup-
port of an extra NLS, further supporting the view of the
m3G-CAP as an independent and eﬃcient import signal.
Since small, single-stranded oligos should have
easy access to the nuclear compartment in both dividing
and non-dividing cells, we believe that in suboptimal con-
ditions, such as low transfection eﬃciencies or less eﬃcient
oligos, higher intranuclear concentrations should be ben-
eﬁcial. It is also important to note that, in vitro, very high
intracellular concentrations can be easily achieved using
A
B
Figure 7. (A) Fold-induction of splice-correction 24h after transfection
of HeLa/Luc705mut with 20-O-methyl antisense (AS) oligos at diﬀerent
concentrations. Correction was measured by testing for luciferase activ-
ity after AS oligo treatment relative to mock treatment. Both oligos
have an additional tri-nucleotide extension (AUA) on their 50-ends to
which an m3G-CAP was added in one of them. Error bars show stan-
dard deviations for at least n=3. (B) RT–PCR. Total cellular RNA
was subjected to RT–PCR. The upper band (268bp) and lower band
(142bp) correspond to the aberrant and correct luciferase mRNA,
respectively. Cp1 and p1 correspond to the antisense oligo (AS705)
with (oligo Cp1) or without (oligo p1) m3G-CAP added. Cp2 and p2
correspond to the scrambled (control) antisense oligo with (oligo Cp2)
or without (oligo p2) m3G-CAP.
Nucleic Acids Research,2009, Vol.37, No. 6 1933transfection reagents, whereas in vivo, in a clinical context,
intracellular oligonucleotides levels may be a limiting
factor. In this case having a nuclear targeting moiety in
the oligo can help to increase local nuclear concentrations.
Enhancing this process may have immediate clinical appli-
cations, since highly promising oligonucleotide-based
treatments aﬀecting splicing have been recently reported
for Duchenne muscular dystrophy (46). An additional fea-
ture may be the possible localization of m3G-CAP cargoes
into speciﬁc splice regions of the nucleus contributing to
the biological eﬀect. In preliminary experiments, we have
studied the nuclear regions where the STV–CAP-oligo is
concentrated, tentatively designated STV-m3G bodies.
Interestingly, these regions diﬀer from Cajal bodies as
well as from the nuclear speckle pattern, both representing
compartments where snRNPs and other splice machinery
components have been found (unpublished data).
In terms of development of new vector-based systems
for nuclear targeting, we believe that the use of a signal
that is naturally present in endogenous RNA molecules
can have potential advantages over methods based on
association of very positively charged NLS peptides with
nucleic acids. These peptides can bind unspeciﬁcally by
electrostatic interactions to the nucleic acids potentially
hampering recognition of the NLS signal by the import
receptors. This could make it diﬃcult to control the prop-
erties of the nucleic acid–NLS complex and to assess their
actual mechanism in transfection protocols. With the use
of m3G-CAP this hurdle no longer poses any problem.
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